Frithz G, Danielson M, Henningsen N, Malmborg R O, Nordström-Ohrberg G, Schröder G
Eur J Cardiol. 1978 Apr-May;7(2-3):131-6.
The antihypertensive effect of beta-adrenoceptor blocking drugs has been documented in a number of papers [10--13] and over the last 10 yr beta-receptor blockade has become a more and more frequent primary therapy for hypertension. During this time, a number of different beta-blockers with various degrees of selectivity, potency and intrinsic sympathomimetic effect have come into use. There have also been attempts to reduce the number of daily doses in beta-adrenoceptor blocking therapy while maintaining the antihypertensive effect [5]. Pindolol (Viskén) is a beta-adrenoceptor blocking agent with intrinsic sympathomimetic effect and is characterized by high potency and long duration.
β-肾上腺素能受体阻断药的降压作用已在多篇论文中得到证实[10 - 13]，在过去10年中，β受体阻断已越来越频繁地成为高血压的主要治疗方法。在此期间，多种具有不同程度选择性、效价和内在拟交感神经活性的β受体阻滞剂开始应用。人们也尝试在维持降压效果的同时减少β肾上腺素能受体阻断治疗的每日用药剂量[5]。吲哚洛尔（心得静）是一种具有内在拟交感神经活性的β肾上腺素能受体阻断剂，其特点是高效价和作用时间长。
